Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464916 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT03464916 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that has completed, run by Sorrento Therapeutics. The registered enrollment target is 10 participants, below the 341-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03464916, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
Conditions Studied
Interventions
- BIOLOGICAL CAR2 Anti-CD38 A2 CAR-T Cells
Study Locations (4)
Florida
- Mayo Clinic Florida - Jacksonville
Minnesota
- Mayo Clinic Minnesota - Rochester
New York
- Icahn School of Medicine - New York
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03464916
The ClinicalTrials.gov registry entry for NCT03464916 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 341-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which CAR2 Anti-CD38 A2 CAR-T Cells is the first listed.
NCT03464916 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT03464916 about?
NCT03464916 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients". The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
What is the current status of trial NCT03464916?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-10-15. Estimated completion is 2022-02-28.
What conditions does trial NCT03464916 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT03464916?
The interventions under investigation include: CAR2 Anti-CD38 A2 CAR-T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03464916?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03464916 being conducted?
This trial has 4 study locations across Florida, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.